Sponsored by
Bizaxofusp (also known as MDNA55) is an immunotoxin that targets and kills cancer cells expressing the interleukin-4 receptor (IL-4R), which is overexpressed in glioblastoma tumors. The latest evidence presented at ASCO 2024 showed that a single treatment of this drug with convection-enhanced delivery directly to the tumor site resulted in median overall survival of 13.5 months and a 12-month overall survival of 56.7% for patients with unresectable recurrent GBM. Additionally, patients who experienced tumor control (based on RANO 2.0 imaging criteria) following treatment had significantly improved median overall survival. Based on these results, a Phase 3 trial is in the works.